Status:
UNKNOWN
The Efficacy of Health Navigation® for Cancer-Related Fatigue in Cancer Survivors
Lead Sponsor:
National Cancer Center, Korea
Collaborating Sponsors:
Samsung Medical Center
Seoul National University Hospital
Conditions:
Cancer-related Fatigue
Eligibility:
All Genders
20-65 years
Phase:
PHASE2
Brief Summary
The objective of this study is 1. to develop a web-based, tailored program for Cancer-related fatigue in cancer survivors, which is comprehensive and evidence-based, 2. to evaluate the efficacy for c...
Detailed Description
\*\*\* Background Cancer-related fatigue (CRF) and its impact on patients' quality of life has been increasing subject of research. Especially, cancer survivors who are complaining of fatigue (modera...
Eligibility Criteria
Inclusion
- Adult (≥20, ≤65)
- moderate to severe fatigue (fatigue VAS ≥4), which persists at least 1 week in the Average Fatigue or the the Worst Fatigue
- Stage I-III
- Within 24 months of completion of primary treatment with curative intent (Surgery, radiotherapy, chemotherapy)
- Cancer survivors who are familiar with the high-speed internet and mobile phone, or cancer survivors who can participate in the web-based program with their supporter's assistance.
Exclusion
- patients undergoing or planning surgery, radiation therapy or chemotherapy
- Major health problem which might cause fatigue or in which exercise/nutrition intervention is contraindicated at the discretion of clinician; from PAR-Q and ACSM test, cardiovascular disease(congestive heart failure, angina), pulmonary disease(chronic obstructive pulmonary disease, restrictive pulmonary disease), uncontrolled hypertension, poorly controlled diabetes and severe musculoskeletal disease and so on
- Sign of infection (body temperature ≥ 37.2℃, WBC≥11,000)
- Thrombocytopenia (platelet count ≤ 100,000/mcl)
- Anemia (Hb ≤ 10g/dL)
- SGOT or SGPT \> 40 IU/L
- Creatinine \> 1.4 mg/dL
- severe psychiatric disorders (psychotic disorder, major depression and so on) or suicidal tendencies
- dyspnea
- evidence of metastasis and recurrence
- ECOG(Eastern Cooperative Oncology Group) performance status of 3-4
- Not Korean speaking
- Not understanding of the study purpose and not written informed consent
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
266 Patients enrolled
Trial Details
Trial ID
NCT01228773
Start Date
July 1 2009
End Date
July 1 2010
Last Update
October 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea